OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 4.

Table. 4.

Comparison of published studies on cfDNA in HCC patients using targeted sequencing

Reference Stage of HCC Sample Genes Median coverage (range) Claimed analytical sensitivity Most common altered gene Detection of ≥1 somatic variants in cfDNA (%) Median variant allele frequency (%)
Howell, et al., 2019 [23] early (39%) and advanced (61%) HCC N= 51 8 486x (IQR: 234x–797x) NA ARID1A 35 11.9 (IQR: 5–42.3)
(8 with paired tumor biopsy)
Kaseb, et al., 2019 [22] advanced HCC N= 206 54–70 NA 0.1% LoD TP53 NA (detection of ≥ 1 alterations in cfDNA: 87.8) 0.49 (range, 0.06–55.03)
Ng, et al., 2018 [25] early (67%) and advanced (33%) HCC N= 30 46 1,239x (703x–3,244x) 0.1% LoD TP53 63 13.7 (range, 0.06–44.9)
(with paired tumor biopsy)
Present study advanced HCC N= 20 3 63,482x (44,765x–81,672x) 0.1% LoD TP53 65 0.13 (range, 0.06–6.99)

Abbreviations: cfDNA, cell-free DNA; HCC, hepatocellular carcinoma; NA, not available; LoD, limit of detection; IQR, interquartile range.

Ann Lab Med 2021;41:198~206 https://doi.org/10.3343/alm.2021.41.2.198

© Ann Lab Med